drugset / Trial / NCT06255626
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
Phase 1/2
Recruiting
215 enrolled
ANRS, Emerging Infectious Diseases
EnnoDc (previously known as LinKinVax) · collabVaccine Research Institute (VRI), France · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine. The main questions that will be studied are : * Is the CD40.RBDv (adjuvanted or not) safe ? * Does the CD40.RBDv (adjuvanted or not) imply an immunologic response ? Participants will receive, depending on their randomization arm, 1 or 2 injections of the CD40.RBDv vaccine or a single injection of approved mRNA vaccine
Timeline
- Start
- 2024-05-27
- Primary completion
- 2025-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD40.RBDv | Vaccine | — | Subcutaneous |